Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...

Pfizer is calling for the FDA to issue guidance on what originator companies can say about cheaper biosimilars of their products, and prevent them using “scare tactics” to keep doctors ...

Pfizer has formed a clinical trial collaboration ... settlement Just as Samsung Bioepis’ partner Sandoz launched a biosimilar to Johnson & Johnson’s Stelara, the Korean company is facing ...

Conservative commentator Megyn Kelly claimed the Pfizer COVID vaccine left her with an auto-immune disorder in explosive new comments on her latest podcast episode Wednesday. Kelly, 54 ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...

Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...

Results from the phase 3 trial showed biosimilar denosumab was comparable to the reference product with regard to efficacy, safety, immunogenicity, PK, and pharmacodynamics (PD) in patients with ...

The launch marks a significant move, as YESINTEK is among the first biosimilar alternatives to Stelara (ustekinumab) to enter the US market. YESINTEK is approved for Crohn’s disease, ulcerative ...